<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467853</url>
  </required_header>
  <id_info>
    <org_study_id>BM2L201910</org_study_id>
    <nct_id>NCT04467853</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Gastric Cancer</brief_title>
  <official_title>A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Legend Biotech Co.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, single-center, open-label, single-dose Phase 1 dose
      finding and extension study to evaluate the safety, tolerability, pharmacokinetics, and
      anti-tumor efficacy profiles of the cell-based LCAR-C18S (hereinafter &quot;LCAR-C18S&quot;) in
      subjects with Claudin18.2-positive advanced gastric adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) and incidence, severity, and type of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>90 days post infusion</time_frame>
    <description>Dose-limiting toxicity (DLT) refers to a drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose. An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD/ RP2D regimen finding</measure>
    <time_frame>90 days post infusion</time_frame>
    <description>Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Venous blood samples will be collected for measurement of CAR-T positive cellular concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of anti-LCAR-C18S antibody and positive sample titer</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Venous blood samples will be collected to measure LCAR-C18S positive cell concentrations and the transgenic level of LCAR-C18S, at the time points when anti-LCAR-C18S antibody serum samples are evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Objective Response Rate (ORR) is defined as the proportion of subjects who achieve CR or PR after treatment via LCAR-C18S cell infusion, and the objective tumor response rate will be calculated for patients with measurable disease per RECIST 1.1 only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Duration of Remission (DOR) is defined as the time from the first documentation of remission (PR or better) to the first documented disease progression evidence (according to RECIST 1.1) of the responders (who achieve PR or better response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival (PFS) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Progression Free Survival (PFS) is defined as the time from the date of first infusion of the LCAR-C18S to the first documented disease progression (according to RECIST 1.1) or death (due to any cause), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Overall Survival (OS) is defined as the time from the date of first infusion of LCAR-C18S to death of the subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Disease Control Rate (DCR) is defined as the proportion of patients with complete response, partial responses and stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) after administration</measure>
    <time_frame>2 years post infusion</time_frame>
    <description>Time to Response (TTR) is defined as the time from the date of first infusion of LCAR-C18S to the date of the first response evaluation of the subject who has met all criteria for PR or better.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>chimeric Antigen Receptor T cell LCAR-C18S Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LCAR-C18S cells</intervention_name>
    <description>Prior to infusion of the LCAR-C18S, subjects will receive a premedication regimen (IV infusion of cyclophosphamide 300 mg/m2 and fludarabine 30mg/m2 once daily (QD) for 3 days; if the subject have a creatinine clearance of 40-70 mL/min/1.73 m2, or for patients &gt; 70 years of age and with a performance status score of 1, dose reduction of fludarabine to 25 mg/m2 and cyclophosphamide to 250 mg/m2 will be allowed). Infusion of LCAR-C18S is scheduled 5 to 7 days after the initiation of the premedication regimen.</description>
    <arm_group_label>chimeric Antigen Receptor T cell LCAR-C18S Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects have been fully informed of the possible risks and benefits of
             participating in the study and have signed the informed consent form;

          2. Age 18-75 years;

          3. Histologically confirmed recurrent or metastatic advanced gastric adenocarcinoma
             (including gastric adenocarcinoma of the gastro-oesophageal junction);

          4. Immunohistochemistry of tumor tissue samples indicates Claudin18.2 positive ;

          5. Previous total gastrectomy/subtotal gastrectomy, and adequate standard of care
             recommended by the National Comprehensive Cancer Network (NCCN 2019 V3) or the Chinese
             Society of Clinical Oncology (CSCO 2019) guidelines for gastric cancer, or comparable
             standard-of-care regimen assessed by the investigator; treatment failure or
             intolerability; subjects who have a positive test result for HER2 must have been
             treated with trastuzumab or are not recommended to use trastuzumab as assessed by the
             investigator;

          6. Subjects with evaluable recurrent or metastatic lesions according to past medical
             history data or imaging findings;

          7. ECOG performance status score of 0-1;

          8. Expected survival ≥ 3 months;

          9. Hematology meets the following criteria: WBC ≥ 2.5 × 109/L; ANC ≥ 1.5 × 109/L; HGB ≥ 9
             g/dL; PLT ≥ 75 × 109/L (Subjects must not have received any growth factor or blood
             transfusion support within 7 days prior to laboratory tests);

         10. Blood biochemistry meets the following criteria: TBIL ≤ 1.5 × ULN (≤ 3 × ULN in
             subjects with liver metastasis); AST and ALT ≤ 3.0 × ULN (≤ 5 × ULN in subjects with
             liver metastasis); serum creatinine ≤ 1.5 × ULN, creatinine clearance &gt; 50 mL/min/1.73
             m2 (per Cockcroft-Gault formula);

         11. Coagulation meets the following criteria: INR &lt; 1.5 × ULN, PT, APTT &lt; 1.5 × ULN;

         12. Women of childbearing age must have a negative blood pregnancy test; subjects of
             childbearing potential must use effective contraception for ≥ 1 year after the final
             study treatment.

        Exclusion Criteria:

          1. Receipt of the following anti-tumor therapies prior to apheresis:

               -  Cytotoxic therapy within 14 days

               -  Small molecule targeted therapy within 14 days or at least 5 half-lives,
                  whichever is longer

               -  Investigational drug therapy within 28 days (if the treatment above is an
                  investigational drug treatment also, a 28-day washout period should be followed)

               -  Treatment with monoclonal antibody within 28 days

               -  Immunomodulatory therapy within 7 days

               -  Radiation therapy within 14 days

          2. Previous CAR-T cell therapy or other cell therapies or therapeutic tumor vaccination
             against any target;

          3. Any previous therapy targeting Claudin18.2;

          4. Presence of local recurrence of gastric lesions;

          5. Brain metastases with central nervous system symptoms;

          6. Pregnant or lactating women;

          7. Uncontrolled diabetes;

          8. Oxygen is required to maintain adequate blood oxygen saturation;

          9. Gastric perforation, pyloric obstruction, complete biliary obstruction, complete or
             incomplete intestinal obstruction requiring clinical intervention, or pleural effusion
             or peritoneal effusion requiring clinical intervention;

         10. Clinically significant liver disorders (including liver cirrhosis, active viral
             hepatitis or other hepatitis);

         11. Positive for any one of hepatitis B surface antigen (HBsAg), hepatitis B virus
             deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus
             ribonucleic acid (HCV RNA), or human immunodeficiency virus antibody (HIV-Ab);

         12. Severe underlying diseases, such as:

               -  Evidence of serious active viral or bacterial infection, or uncontrolled systemic
                  fungal infections

               -  Active or unstable auto-immune diseases or history of auto-immune diseases within
                  3 years and that may relapse

               -  Evident clinical evidence of dementia or mental status changes

         13. Significant bleeding tendency, such as haemorrhage of digestive tract, coagulation
             disorders, and hyposplenism;

         14. New York Heart Association (NYHA) Class III or IV congestive heart failure or left
             ventricular ejection fraction (LVEF) &lt; 50%; unstable angina, myocardial infarction or
             coronary artery bypass grafting (CABG) in the past 6 months; history of severe
             non-ischemic cardiomyopathy; or severe uncontrolled arrhythmia;

         15. In addition to non-melanoma skin cancer or cervical cancer in situ, other malignant
             tumors in the past 5 years;

         16. Patients with chronic diseases requiring treatment with systemic corticosteroids or
             other immunosuppressive agents; use of systemic corticosteroid hormone (≥ 30 mg of
             prednisone or equivalent dose of other corticosteroids) or other immunosuppressive
             agents within 30 days prior to apheresis, with the exception of topical, ocular,
             intra-articular, intranasal, and inhalational corticosteroids; or a brief course of
             corticosteroids for prophylaxis (e.g., prophylaxis for contrast dye allergy)

         17. Had a stroke or epilepsy within 6 months prior to signing ICF;

         18. Receipt of live attenuated vaccine within 4 weeks prior to apheresis;

         19. Subjects who have undergone major surgery within 2 weeks prior to apheresis or are
             scheduled to undergo surgery during the study or within 2 weeks after study treatment
             (Note: Subjects who plan to undergo a surgery under local anesthesia may participate
             in this study);

         20. Known allergy to excipients and related adjuvants (including but not limited to DMSO
             and dextran-40) of the study drug;

         21. Any condition that, in the opinion of the investigator, will make the subject
             unsuitable for participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, MD,PhD</last_name>
    <phone>+86</phone>
    <phone_ext>13761222111</phone_ext>
    <email>lijin@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenjuan Qi, bachelor</last_name>
    <phone>+86</phone>
    <phone_ext>13645170324</phone_ext>
    <email>qiwenjuan@legendbiotech.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

